Experienced in Conjunctivitis (Pink Eye)

Dr. Victor H. Gonzalez

Ophthalmology | General Surgery
Valley Retina Institute P.A.
1205 Ed Carey Dr, 
Harlingen, TX 
Accepting New Patients
Experienced in Conjunctivitis (Pink Eye)
Valley Retina Institute P.A.
1205 Ed Carey Dr, 
Harlingen, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Victor Gonzalez is an Ophthalmologist and a General Surgeon in Harlingen, Texas. Dr. Gonzalez is rated as an Experienced provider by MediFind in the treatment of Conjunctivitis (Pink Eye). His top areas of expertise are Diabetic Macular Edema (DME), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), and Vitrectomy. Dr. Gonzalez is currently accepting new patients.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Ophthalmology
General Surgery
Licenses
Surgery in TX
Ophthalmology in TX
Hospital Affiliations
Doctors Hospital Of Laredo
Reeves County Hospital District
Fort Duncan Medical Center
Val Verde Regional Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

VALLEY RETINA INSTITUTE P.A.
1205 Ed Carey Dr, Harlingen, TX 78550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Enrollment Status: Terminated
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: GSK2798745
Study Phase: Phase 1
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy
A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of RBM-007 Monotherapy and RBM-007 in Combination With Eylea® Compared to Eylea® Monotherapy
Enrollment Status: Completed
Publish Date: June 08, 2023
Intervention Type: Drug
Study Drugs: RBM-007 Injectable Solution, Aflibercept, Sham
Study Phase: Phase 2
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
Enrollment Status: Completed
Publish Date: June 08, 2023
Intervention Type: Drug
Study Drug: RBM-007
Study Phase: Phase 2
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 4
Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity
Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 3
Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
Enrollment Status: Completed
Publish Date: September 25, 2018
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial.
Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial.
Journal: EClinicalMedicine
Published: June 25, 2025
Similar Doctors
Distinguished in Conjunctivitis (Pink Eye)
Dr. Pankajkumar G. Shah
Ophthalmology
Distinguished in Conjunctivitis (Pink Eye)
Dr. Pankajkumar G. Shah
Ophthalmology

Shah Eye Center PA

1506 E Griffin Pkwy, 
Mission, TX 
 (39.1 miles away)
956-583-0202
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Pankajkumar Shah is an Ophthalmologist in Mission, Texas. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Conjunctivitis (Pink Eye). His top areas of expertise are Cataract, Pterygium, Dry Eye Syndrome, and Conjunctivitis (Pink Eye). Dr. Shah is currently accepting new patients.

Distinguished in Conjunctivitis (Pink Eye)
Dr. Stephen R. Hook
Ophthalmology
Distinguished in Conjunctivitis (Pink Eye)
Dr. Stephen R. Hook
Ophthalmology

Thurmond Eye Associates PLLC

1519 E 6th St, 
Weslaco, TX 
 (18.6 miles away)
956-968-3171
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Stephen Hook is an Ophthalmologist in Weslaco, Texas. Dr. Hook is rated as a Distinguished provider by MediFind in the treatment of Conjunctivitis (Pink Eye). His top areas of expertise are Subconjunctival Hemorrhage, Blepharitis, Conjunctivitis (Pink Eye), and Hyphema. Dr. Hook is currently accepting new patients.

Advanced in Conjunctivitis (Pink Eye)
Dr. Alexander P. Sudarshan
Ophthalmology
Advanced in Conjunctivitis (Pink Eye)
Dr. Alexander P. Sudarshan
Ophthalmology

Alexander P. Sudarshan MD PA

1058 E Los Ebanos Blvd, 
Brownsville, TX 
 (19.6 miles away)
956-541-4828
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Alexander Sudarshan is an Ophthalmologist in Brownsville, Texas. Dr. Sudarshan is rated as a Distinguished provider by MediFind in the treatment of Conjunctivitis (Pink Eye). His top areas of expertise are Pterygium, Diabetic Retinopathy, Cataract, and Glaucoma. Dr. Sudarshan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gonzalez's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile